STAT NewsOriginal article
STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more
Phase 3negativeNegative
AI Analysis
Summary
Eyepoint's Phase 3 trial for an experimental age-related blindness treatment failed to meet its primary endpoint. The negative trial result represents a significant setback for the company.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Phase 3 trial fell short of its primary goal
Importance:7/10
Sentiment:
-0.80
Phase 3 failureophthalmologyage-related macular degeneration
Related Companies
Read the original article
Published by STAT News on August 18, 2026 1:25 PM